Home » Regions » Europe » GamaMabs Pharma raises €15m in series B financing round

GamaMabs Pharma raises €15m in series B financing round

Tuesday, December 15, 2015

GamaMabs Pharma, a Toulouse, France-based biotechnology company developing optimized therapeutic antibodies for the treatment of cancer, today announced the completion of a €15 million ($15.9 million) series B financing round.

The round was led by a new investor, BioDiscovery 4, a fund managed by Edmond de Rothschild Investment Partners (EdRIP). All existing GamaMabs investors (InnoBio, Irdinov, Alto Invest and iXO Private Equity) also subscribed to the round. The company raised €3.6 million ($3.8 million) in 2013 in a series A funding round led by InnoBio (Bpifrance).

The fundraising will primarily fund the phase I and phase II clinical trials of GM102 (3C23K), a monoclonal antibody targeting gynecological cancers. GM102 is a first-in-class antibody and the company’s most advanced product. It targets AMHRII, a protein expressed on tumor cells’ membrane surface in various gynecological cancers. It also activates immune cells present in the tumor microenvironment. The first-in-man clinical trials of GM102 will start in the first half of 2016.

“We are thrilled to welcome EdRIP, a high-profile investor that supports our goal to build GamaMabs into a market leader specialized in the treatment of gynecological cancers,” said Philippe Boucheron, deputy director of life sciences at Bpifrance Investissement. “The company is now well-equipped to demonstrate the clinical benefits of its products.”

“We are delighted with the trust expressed by EdRIP and all our current investors. This fundraising will fund proof-of-concept clinical trials on our GM102 antibody in patients with recurrent gynecologic cancers which represent major unmet medical needs,” said GamaMabs CEO Stéphane Degove.

“This financing concludes a very positive year for GamaMabs, including successfully completed GM102 preclinical trials, demonstrating its very favorable efficacy-safety profile,” said Dr. Jean-François Prost, vice president of R&D and strategy at GamaMabs.

Following the fundraising, Gilles Nobécourt, partner at EdRIP, and Professor Thierry Hercend will join GamaMabs’ board of directors.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!